Why Did Zevra Therapeutics (ZVRA) Stock Move Up +17.86% Today?
Key Takeaways
- ZVRA shares surged approximately +17.86% on March 10, 2026, driven by a blockbuster Q4 and full-year 2025 earnings report released before the market open
- Primary catalyst: Q4 2025 EPS of $0.19 crushed the consensus estimate of $0.05 — a 280% beat — while revenue of $34.1 million exceeded forecasts by 21.57%
- Secondary driver: Full-year 2025 revenue of $106.5 million represented a 351% year-over-year surge, powered almost entirely by the rapid commercial uptake of MIPLYFFA® for Niemann-Pick disease type C (NPC)
- The company swung from a net loss of $105.5 million in 2024 to net income of $83.2 million in 2025, marking a dramatic profitability inflection
- Zevra ended 2025 with $238.9 million in cash and securities, signaling financial independence from capital markets
- Traders are watching for 2026 guidance updates, continued MIPLYFFA patient enrollment growth, and any pipeline expansion announcements
Opening Summary
Zevra Therapeutics, Inc. (ZVRA) is a commercial-stage rare disease biopharmaceutical company focused on developing and commercializing treatments for serious medical conditions, most notably MIPLYFFA® (arimoclomol) for Niemann-Pick disease type C — an ultra-rare, progressive, and fatal neurological disorder. On March 10, 2026, shares of ZVRA surged approximately +17.86%, rising from a prior closing price of $9.36 to trade around $11.03 during the morning session. The move was triggered by the company's pre-market release of Q4 and full-year 2025 financial results, which materially outpaced Wall Street expectations on both the top and bottom lines.
Earnings Beat Drives the Rally
Zevra's Q4 2025 report delivered a powerful combination of revenue beats and a full profitability reversal. The company posted Q4 EPS of $0.19 — a 280% surprise above the $0.05 consensus estimate — while Q4 revenue of $34.1 million came in 21.57% ahead of the $28.05 million forecast. That Q4 revenue figure also represented 31% sequential growth compared to the prior quarter, reflecting accelerating commercial momentum.
For the full year, ZVRA reported net revenues of $106.5 million, up from just $23.6 million in 2024 — a 351% year-over-year increase. The company also flipped from a 2024 net loss of $105.5 million to full-year 2025 net income of $83.2 million, or $1.35 per diluted share. That kind of rare-disease commercial execution at scale is precisely the type of result that compresses short-seller positions and draws in momentum buyers.
MIPLYFFA: The Commercial Engine
MIPLYFFA® accounted for $87.4 million of the company's $106.5 million in 2025 full-year revenue — roughly 82% of total sales — cementing its status as the primary growth driver for ZVRA. In Q4 alone, MIPLYFFA generated $26.4 million in net revenue, up dramatically from $12 million in total Q4 2024 revenues. The drug, which received FDA approval for Niemann-Pick disease type C in late 2024, has seen accelerating patient enrollment, with 24 new prescription enrollment forms filed in Q4 2025 and 161 cumulative since launch.
This trajectory suggests the drug is still in the early-to-middle stages of penetrating its target patient population. With only approximately 500–1,000 NPC patients estimated in the United States, each additional patient represents a meaningful revenue contribution given the ultra-rare disease pricing structure — a tailwind that Wall Street is clearly reassessing in ZVRA's valuation following today's results.
Strong Balance Sheet Adds to Confidence
Beyond the income statement, ZVRA's cash position reinforced investor confidence. The company closed 2025 with $238.9 million in cash, cash equivalents, and securities. That war chest, management indicated, is sufficient to fund strategic priorities without requiring additional capital raises — removing a key overhang that has historically weighed on small- and mid-cap biotech stocks. Operating expenses for full-year 2025 also declined year-over-year to $90.4 million from $97.0 million in 2024, despite the company continuing to invest in commercial launch activities.
Market Context and Trading Activity
Volume in ZVRA was significantly elevated on March 10, with early session trading tracking well above the stock's average daily volume of approximately 917,000 shares. The broader biotech sector provided a constructive backdrop, with rare-disease commercial-stage names attracting renewed interest following a period of sector-wide consolidation. Prior to today's session, ZVRA had been trading below both its 50-day ($8.78) and 200-day ($9.07) moving averages, meaning today's gap-up open simultaneously triggered technical buy signals across multiple timeframes. The stock's 52-week range of $6.19–$13.16 places today's move squarely in recovery territory, with the prior 52-week high remaining a key overhead resistance level to watch.
Trending AI Robots
For traders looking to systematically capitalize on momentum events like today's earnings-driven surge in ZVRA, Tickeron's Trending AI Robots page offers a curated look at the platform's highest-performing automated trading bots under current market conditions. Tickeron operates hundreds of AI-powered bots covering thousands of tickers, spanning strategies from swing trading and trend-following to mean-reversion and breakout systems — each with distinct timeframes, risk parameters, and performance metrics. Only the bots demonstrating the strongest real-time results are featured in the Trending section, making it a practical resource for traders seeking data-driven, rules-based exposure. Investors interested in systematically navigating volatile, catalyst-driven moves in biotech and beyond may find Tickeron's AI robot suite worth exploring.
What Comes Next for ZVRA
Looking ahead, the key question for ZVRA investors is whether MIPLYFFA's patient enrollment trajectory can sustain the revenue growth pace seen in the second half of 2025. Management's 2026 guidance — and any commentary on international expansion or new patient identification programs — will be closely scrutinized following today's earnings call. The company's pipeline beyond MIPLYFFA, including OLPRUVA and its AZSTARYS® royalty stream, also represents optionality that analysts have not yet fully priced in. Analyst consensus currently sits at a "Moderate Buy" with an average price target of $22.80, implying substantial upside even after today's rally. Risks include potential regulatory developments, payer coverage decisions affecting MIPLYFFA reimbursement, and broader macro headwinds that could pressure biotech valuations across the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ZVRA in downward trend: price may drop because broke its higher Bollinger Band on March 10, 2026
ZVRA broke above its upper Bollinger Band on March 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 36 similar instances where the stock broke above the upper band. In of the 36 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ZVRA moved out of overbought territory on March 11, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where ZVRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZVRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on April 02, 2026. You may want to consider a long position or call options on ZVRA as a result. In of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ZVRA just turned positive on April 07, 2026. Looking at past instances where ZVRA's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
ZVRA moved above its 50-day moving average on March 31, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZVRA advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 155 cases where ZVRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZVRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.595) is normal, around the industry mean (26.162). P/E Ratio (7.015) is within average values for comparable stocks, (45.457). ZVRA's Projected Growth (PEG Ratio) (10.667) is very high in comparison to the industry average of (1.767). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (5.094) is also within normal values, averaging (317.372).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZVRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement